within Pharmacolibrary.Drugs.ATC.B;

model B02BD02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 3.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,
    adminCount     = 1,
    Vd             = 5e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Coagulation factor VIII is a multifunctional glycoprotein playing a crucial role in the blood clotting cascade. It is primarily used for the treatment and prophylaxis of bleeding in individuals with hemophilia A, a genetic deficiency of factor VIII. Factor VIII is approved as a replacement therapy and is administered as either plasma-derived or recombinant concentrate products.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with severe hemophilia A who received a single intravenous dose of recombinant factor VIII concentrate.</p><h4>References</h4><ol><li><p>Hermans, C, &amp; Pierce, GF (2024). Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind. <i>Journal of thrombosis and haemostasis : JTH</i> 22(7) 1844–1846. DOI:<a href=&quot;https://doi.org/10.1016/j.jtha.2024.04.010&quot;>10.1016/j.jtha.2024.04.010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38679336/&quot;>https://pubmed.ncbi.nlm.nih.gov/38679336</a></p></li><li><p>Gaitonde, P, et al., &amp; Balu-Iyer, SV (2015). Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 66 157–162. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2014.10.010&quot;>10.1016/j.ejps.2014.10.010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25459532/&quot;>https://pubmed.ncbi.nlm.nih.gov/25459532</a></p></li><li><p>Nestorov, I, et al., &amp; Rogge, M (2015). Population pharmacokinetics of recombinant factor VIII Fc fusion protein. <i>Clinical pharmacology in drug development</i> 4(3) 163–174. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.167&quot;>10.1002/cpdd.167</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27140796/&quot;>https://pubmed.ncbi.nlm.nih.gov/27140796</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B02BD02;
